Sorrento Therapeutics, Inc. · OTC:SRNE

Sorrento Therapeutics, Inc. financial statements

Sorrento Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Revenue62.8M52.9M40.0M31.4M21.2M151.9M8.15M4.59M3.83M460.1K
Cost of revenue33.5M13.0M9.94M12.2M7.06M3.94M811.0K1.95M2.04M4.44K
Gross profit29.4M39.9M30.0M19.2M14.1M147.9M7.34M2.64M1.78M455.7K
Research and development221.2M206.9M111.3M106.9M77.0M55.5M42.2M31.3M24.0M9.02M
Selling, general and administrative182.3M196.9M116.2M103.6M63.6M38.3M24.2M20.1M9.99M6.32M
Operating income-378.5M-368.0M-201.5M-195.2M-150.4M25.3M-96.8M-74.0M-34.7M-21.7M
Depreciation and amortization13.2M12.5M11.0M11.0M9.05M7.08M2.88M2.37M3.18M1.29M
EBITDA-365.3M-355.6M-190.5M-184.2M-141.4M32.4M-93.9M-71.6M-31.6M-20.4M
Interest expense8.57M10.2M20.2M36.1M57.6M4.98M1.61M1.65M1.63M253.2K
Income before tax-561.7M-462.5M-310.6M-359.6M-213.8M15.3M-64.8M-13.8M-36.4M-21.9M
Income tax-2.42M-33.5M-2.01M-473.0K-6.27M-36.0M-896.0K36.3M-1.70M0
Net income-559.3M-429.0M-308.6M-359.1M-203.5M9.13M-60.9M-45.8M-34.7M-21.9M
Earnings per share, basic-1.33-1.46-1.34-2.56-1.920.13-1.21-1.24-1.30-1.46

Balance sheet

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash and equivalents23.6M36.7M56.5M22.5M158.7M20.4M82.4M39.0M71.9M31.7M
Short-term investments26.3M90.2M256.4M297.0K441.0K1.11M97.4M00
Receivables24.5M18.7M15.5M14.5M4.36M3.93M2.98M2.62M732.0K394.2K
Inventory9.98M8.11M1.83M3.36M2.90M00000
Current assets96.4M173.0M86.2M67.6M179.6M29.7M89.7M141.0M73.9M32.6M
Property, plant and equipment52.0M41.3M31.9M29.9M24.4M19.3M12.7M7.25M2.28M2.44M
Goodwill80.3M79.5M43.6M38.3M38.3M38.3M41.5M20.6M24.0M24.0M
Total assets472.8M694.8M535.8M557.6M624.1M431.6M401.6M343.5M141.5M92.6M
Accounts payable47.5M27.4M24.7M27.6M13.8M9.91M8.28M1.34M1.66M2.15M
Current liabilities327.9M139.5M96.5M115.2M61.6M79.0M76.1M30.9M9.56M5.48M
Long-term debt19.1M110.6M92.3M199.1M223.1M5.21M47.1M4.39M8.83M4.43M
Total debt134.5M237.6M169.4M290.8M233.3M5.21M47.3M9.23M12.1M4.80M
Total liabilities494.5M616.7M395.1M524.9M416.6M225.0M315.1M202.6M32.8M25.8M
Shareholders' equity-21.7M78.1M140.7M32.8M207.5M206.6M86.5M140.9M108.7M66.8M
Shares outstanding419.3M294.8M229.8M140.5M106.2M70.4M50.4M36.9M26.7M15.0M

Cash flow

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash from operations-293.9M-281.8M-159.5M-173.0M-111.8M-99.2M-70.9M-42.1M-28.8M-16.5M
Capital spending-13.7M-8.87M-37.6M-11.4M-11.2M-11.0M-6.86M-3.71M-591.0K-931.3K
Free cash flow-307.5M-290.7M-197.1M-184.4M-123.0M-110.2M-77.8M-45.8M-29.4M-17.4M
Cash from investing-28.5M79.8M-39.9M-38.2M-21.2M-16.5M-17.5M12.6M-10.6M-503.5K
Cash from financing311.7M181.3M174.2M78.9M326.0M53.7M131.7M-3.35M79.6M43.6M
Dividends paid00000
Share buybacks403.5M217.2M-55.0M56.5M61.4M57.9M-15.6M1.75M72.1M37.7M
Change in cash-13.0M-19.8M-24.3M-132.6M192.9M-62.0M43.4M-32.9M40.2M26.6M